Izabela Rozenberg

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.

IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.

Journal: Experimental dermatology

Published: January 07, 2022

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.

Journal: The Lancet. Haematology

Published: October 12, 2020

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 28, 2020

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

Journal: Haematologica

Published: August 06, 2020

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Journal: Human molecular genetics

Published: June 20, 2018

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Journal: Human molecular genetics

Published: January 24, 2018

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.

Journal: Clinical epigenetics

Published: November 27, 2015

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: November 06, 2014

Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo.

Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo.

Journal: European heart journal

Published: January 15, 2014

Restraint stress enhances arterial thrombosis in vivo--role of the sympathetic nervous system.

Restraint stress enhances arterial thrombosis in vivo--role of the sympathetic nervous system.

Journal: Stress (Amsterdam, Netherlands)

Published: November 13, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026